Skip to content Skip to footer

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Shots:

  • Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25
  • As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in the EU or in Germany, France, Italy, Spain or UK as per CVR agreement
  • Checkpoint, Sun, & Fortress Biotech have also signed royalty agreement, granting Fortress royalties on future Unloxcyt sales during a specified term, replacing prior rights from Checkpoint’s establishment after closing

Ref: Sun Pharma | Image: Checkpoint Therapeutics

Related News:- Checkpoint Therapeutics’ Unloxcyt (Cosibelimab-ipdl) Receives the US FDA’s Approval for Cutaneous Squamous Cell Carcinoma (cSCC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]